ES2429041T3 - Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores - Google Patents

Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores Download PDF

Info

Publication number
ES2429041T3
ES2429041T3 ES05789195T ES05789195T ES2429041T3 ES 2429041 T3 ES2429041 T3 ES 2429041T3 ES 05789195 T ES05789195 T ES 05789195T ES 05789195 T ES05789195 T ES 05789195T ES 2429041 T3 ES2429041 T3 ES 2429041T3
Authority
ES
Spain
Prior art keywords
entry
cancer
substance
combination
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05789195T
Other languages
English (en)
Spanish (es)
Inventor
Paul Polakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2429041T3 publication Critical patent/ES2429041T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES05789195T 2004-06-18 2005-06-17 Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores Expired - Lifetime ES2429041T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58074504P 2004-06-18 2004-06-18
US580745P 2004-06-18
PCT/US2005/021378 WO2006009805A2 (en) 2004-06-18 2005-06-17 Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors

Publications (1)

Publication Number Publication Date
ES2429041T3 true ES2429041T3 (es) 2013-11-12

Family

ID=35351719

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05789195T Expired - Lifetime ES2429041T3 (es) 2004-06-18 2005-06-17 Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores

Country Status (7)

Country Link
US (2) US8147827B2 (enExample)
EP (1) EP1786466B1 (enExample)
JP (2) JP5039544B2 (enExample)
AU (1) AU2005265067B2 (enExample)
CA (1) CA2570887C (enExample)
ES (1) ES2429041T3 (enExample)
WO (1) WO2006009805A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998255B1 (en) * 1999-09-24 2006-02-14 Solvay Pharmaceuticals B.V. Human G-protein coupled receptor
CA2618542A1 (en) * 2005-08-09 2007-02-15 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
US20080124329A1 (en) * 2006-07-05 2008-05-29 Schreiner George F Conditioned Cell Immunization
IN2009KN02404A (enExample) * 2006-12-14 2015-08-07 Medarex Inc
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
JP2011074093A (ja) * 2008-06-02 2011-04-14 Univ Of Tokyo 抗がん剤
WO2009147695A1 (ja) * 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
JP4686733B2 (ja) * 2008-06-02 2011-05-25 国立大学法人 東京大学 抗がん剤
EP2283862B1 (en) * 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
ES2574236T3 (es) 2009-04-20 2016-06-16 Oxford Biotherapeutics Ltd Anticuerpos específicos para cadherina-17
WO2012118806A2 (en) * 2011-02-28 2012-09-07 The Regents Of The University Of California Compositions and methods for detecting and treating cancer
JP5771123B2 (ja) * 2011-11-09 2015-08-26 株式会社 資生堂 プロフィラグリンｃ末端ドメイン特異的抗体及びその用途
JP2013235003A (ja) * 2012-05-10 2013-11-21 Fujita Gakuen 細胞におけるｄｎａ損傷の検出方法及びｄｎａ鎖切断応答性細胞表面抗原に対する抗体
GB201213652D0 (en) * 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
RU2664180C2 (ru) 2013-04-15 2018-08-15 Регенерон Фармасьютикалз, Инк. Маркеры ответа опухолевых клеток на противораковую терапию
CN105764501A (zh) * 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
WO2020106050A1 (ko) * 2018-11-20 2020-05-28 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
EP2325321A1 (en) 1999-05-28 2011-05-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
US6652853B2 (en) * 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
EP1408974A2 (en) 2001-07-23 2004-04-21 Epidauros Biotechnologie AG Methods for treatment of cancer using irinotecan based on ugt1a1
JP2006522163A (ja) 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用

Also Published As

Publication number Publication date
US20120201822A1 (en) 2012-08-09
EP1786466A2 (en) 2007-05-23
JP5039544B2 (ja) 2012-10-03
WO2006009805A2 (en) 2006-01-26
AU2005265067B2 (en) 2010-12-16
JP5719322B2 (ja) 2015-05-13
CA2570887C (en) 2014-09-16
US20060003960A1 (en) 2006-01-05
WO2006009805A3 (en) 2007-01-04
US8147827B2 (en) 2012-04-03
CA2570887A1 (en) 2006-01-26
AU2005265067A1 (en) 2006-01-26
JP2008503480A (ja) 2008-02-07
JP2012144538A (ja) 2012-08-02
EP1786466B1 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
JP5719322B2 (ja) 腫瘍の治療
Ladner The role of dUTPase and uracil-DNA repair in cancer chemotherapy
CN114127121B (zh) 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
JP7264580B2 (ja) 骨髄線維症を処置するための方法および組成物
CN108178789B (zh) 内皮糖蛋白多肽及其用途
KR102129636B1 (ko) Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
ES2810700T3 (es) Metilación del promotor de PD-L1 en cáncer
EP3038647B1 (en) Combination therapy for the treatment of glioblastoma
ES2611337T3 (es) Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
JP2023096078A (ja) 自己免疫疾患およびがんを処置するための組成物および方法
TW201106972A (en) Combination treatments
US20220396839A1 (en) Methods of detecting a fusion gene encoding a neoantigen
US20250146076A1 (en) Alk gene fusions and uses thereof
KR20250004732A (ko) 그렘린-1 길항제와 사이티딘 유사체 또는 데옥시사이티딘 유사체의 조합
KR101954735B1 (ko) 항암 약제 내성 암의 예방 또는 치료용 약학적 조성물
KR20250052418A (ko) 항-ccr8 항체 및 그의 용도
EP4399330A1 (en) Gene fusions in sarcoma
EP4423302A2 (en) Novel kinase fusions detected by liquid biopsy
RU2797489C2 (ru) Дезоксипроизводные цитидина или уридина для применения при лечении рака
US20240335465A1 (en) A non-canonical signaling activity of cgamp triggers dna damage response signaling
KR20250044292A (ko) 변형된 항-갈렉틴-9 항체 및 그의 용도